David Hudesman

3.7k total citations · 1 hit paper
87 papers, 1.7k citations indexed

About

David Hudesman is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, David Hudesman has authored 87 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Genetics, 57 papers in Epidemiology and 27 papers in Surgery. Recurrent topics in David Hudesman's work include Inflammatory Bowel Disease (70 papers), Microscopic Colitis (51 papers) and Eosinophilic Esophagitis (13 papers). David Hudesman is often cited by papers focused on Inflammatory Bowel Disease (70 papers), Microscopic Colitis (51 papers) and Eosinophilic Esophagitis (13 papers). David Hudesman collaborates with scholars based in United States, Portugal and Canada. David Hudesman's co-authors include Jordan E. Axelrad, Sam S. Chang, P’ng Loke, Ashley M. Hine, José U. Scher, Samrachana Adhikari, Rebecca H. Haberman, Peter Izmirly, Di Yan and Andrea L. Neimann and has published in prestigious journals such as New England Journal of Medicine, Cell and SHILAP Revista de lepidopterología.

In The Last Decade

David Hudesman

82 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease

2019 335 citations Ashley M. Hine, P’ng Loke et al. profile →

Peers

David Hudesman

GENET

EPIDE

IMMUN

SURGE

Terry Harville United States

Anna Šedivá Czechia

Ludmila Prokunina‐Olsson United States

Robert P. Nelson United States

Aurélie Cobat France

Isabelle Meyts Belgium

Maya Ram Israel

Edward J Carr United Kingdom

Ryo Sumazaki Japan

Carlos A. Cañas Colombia

Terry Harville United States

David Hudesman

353 ×0.5

GENET

383 ×0.6

EPIDE

991 ×2.5

IMMUN

207 ×0.6

187 ×0.5

SURGE

Citations per year, relative to David Hudesman David Hudesman (= 1×) peers Terry Harville

Countries citing papers authored by David Hudesman

Since Specialization

Citations

This map shows the geographic impact of David Hudesman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Hudesman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Hudesman more than expected).

Fields of papers citing papers by David Hudesman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Hudesman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Hudesman. The network helps show where David Hudesman may publish in the future.

Co-authorship network of co-authors of David Hudesman

This figure shows the co-authorship network connecting the top 25 collaborators of David Hudesman. A scholar is included among the top collaborators of David Hudesman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Hudesman. David Hudesman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rojanasopondist, Pakdee, Cristina Fernández, Alice Li, et al.. (2025). Safety and Efficacy of Ustekinumab and Vedolizumab Among Older Adults with Inflammatory Bowel Disease. Digestive Diseases and Sciences. 71(2). 594–604.

Schreiber, S, Aoife Keohane, Baojin Zhu, et al.. (2025). P1071 Trajectories of response in patients with moderately-to-severely active ulcerative colitis treated with mirikizumab: Results from the LUCENT-1 study. Journal of Crohn s and Colitis. 19(Supplement_1). i1975–i1976. 1 indexed citations

Jang, Kyung Ku, David Hudesman, Drew R. Jones, et al.. (2024). Tofacitinib Uptake by Patient-Derived Intestinal Organoids Predicts Individual Clinical Responsiveness. Gastroenterology. 167(7). 1453–1456.e5. 7 indexed citations

Faye, Adam S., Corey A. Siegel, Gil Melmed, et al.. (2024). CHRONOLOGICAL AGE INFLUENCES TREATMENT DECISION IN INFLAMMATORY BOWEL DISEASE: AN IBD QORUS COLLABORATIVE STUDY. Gastroenterology. 166(3). S111–S112.

Faye, Adam S., Corey A. Siegel, Gil Melmed, et al.. (2024). CHRONOLOGICAL AGE INFLUENCES TREATMENT DECISION IN INFLAMMATORY BOWEL DISEASE: AN IBD QORUS COLLABORATIVE STUDY. Inflammatory Bowel Diseases. 30(Supplement_1). S80–S81.

Janak, Jud C., Anita M. Loughlin, Page C. Moore, et al.. (2024). The Burden of Work Productivity and Activity Impairment in Patients with Psoriasis, Psoriatic Arthritis, Ulcerative Colitis, and Crohn’s Disease. Digestive Diseases and Sciences. 69(8). 2784–2795. 1 indexed citations

Herfarth, Hans, Anita Afzali, Monika Fischer, et al.. (2023). Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry. Clinical and Translational Gastroenterology. 15(3). e00669–e00669. 1 indexed citations

Hudesman, David, Feza H. Remzi, Jordan E. Axelrad, et al.. (2023). Risk factors for incomplete telehealth appointments among patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology. 16. 1108341207–1108341207.

Dulai, Parambir S., Victoria Rai, Laura E. Raffals, et al.. (2022). Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. The American Journal of Gastroenterology. 117(8). 1288–1295. 5 indexed citations

10.

Long, Millie D., Anita Afzali, Monika Fischer, et al.. (2022). Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting. Inflammatory Bowel Diseases. 29(4). 570–578. 18 indexed citations

11.

Battat, Robert, David Hudesman, Douglas C. Wolf, et al.. (2021). Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index. Crohn s & Colitis 360. 3(3). otab032–otab032. 5 indexed citations

12.

Hong, Simon, Feza H. Remzi, Sam S. Chang, et al.. (2021). Implementation of an Inpatient IBD Service Is Associated with Improvement in Quality of Care and Long-Term Outcomes. Digestive Diseases and Sciences. 66(11). 3753–3759. 3 indexed citations

13.

Devlin, Joseph C., Jordan E. Axelrad, Ashley M. Hine, et al.. (2021). Single-Cell Transcriptional Survey of Ileal-Anal Pouch Immune Cells From Ulcerative Colitis Patients. Gastroenterology. 160(5). 1679–1693. 50 indexed citations

14.

Chang, Sam S. & David Hudesman. (2020). First-Line Biologics or Small Molecules in Inflammatory Bowel Disease: a Practical Guide for the Clinician. Current Gastroenterology Reports. 22(2). 7–7. 24 indexed citations

15.

Tang, Mei San, Rowann Bowcutt, Jacqueline M. Leung, et al.. (2017). Integrated Analysis of Biopsies from Inflammatory Bowel Disease Patients Identifies SAA1 as a Link Between Mucosal Microbes with TH17 and TH22 Cells. Inflammatory Bowel Diseases. 23(9). 1544–1554. 30 indexed citations

16.

Shmidt, Eugenia, Adam C. Winters, Khadija Chaudrey, et al.. (2017). P-040 Assessing Risk Factors Predicting Loss of Response to Vedolizumab in Ulcerative Colitis and Crohn's Disease: Outcomes from the VICTORY Consortium. Inflammatory Bowel Diseases. 23. 2 indexed citations

17.

Smukalla, Scott, et al.. (2017). Receptive Anal Intercourse in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 23(8). 1285–1292. 10 indexed citations

18.

Dulai, Parambir S., Siddharth Singh, Xiaoqian Jiang, et al.. (2016). The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium. The American Journal of Gastroenterology. 111(8). 1147–1155. 216 indexed citations

19.

Hudesman, David. (2014). Capsule endoscopy in Crohn’s disease: Are we seeing any better?. World Journal of Gastroenterology. 20(36). 13044–13044. 10 indexed citations

20.

Lipp, Michael, David Hudesman, Pauline Suwandhi, et al.. (2011). Detection of Esophageal Varices Using CT and MRI. Digestive Diseases and Sciences. 56(9). 2696–2700. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact